Ninlaro
Takeda’s Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma
March 11, 2020Research and Development, Sales and Marketing Ninlaro, Takeda, multiple myeloma, pharma
Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed …
Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma
November 8, 2019Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …
Takeda’s Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma
July 12, 2018Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 …
Takeda’s Ninlaro knocked back by NICE for second time
September 5, 2017Research and Development, Sales and Marketing Ninlaro, Takeda, biotech, drugs, pharma, pharmaceutical
NICE has revealed that the outcome of its consultation process for Ninlaro (ixazomib), Takeda’s treatment for relapsed or refractory multiple …
Takeda in myeloma research drive
January 14, 2016Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma
Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …
Takeda’s Ninlaro extends myeloma survival in trial
December 7, 2015Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma
Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …
